Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial

BMC Public Health

Patrizia M Carrieri³  Bruno Spire³  Jean-Claude Desenclos⁴  Jean-Francois Aubertin¹  Alain Morel⁵  Marion Mora³  Julien Cohen³  Laurent Michel²  Perrine Roux³ 

[1] Thionville, France;Centre Pierre Nicole, Paris, France;ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d’Azur, Marseille, France;Institut de Veille Sanitaire, Saint-Maurice, France;Oppelia, Paris, France

关键词: Opioid maintenance treatment;    Opioid use;    Overdose;    Initiation;    Primary care;    Methadone;   

Others  :  1163487
DOI  :  10.1186/1471-2458-12-488

 received in 2012-03-14, accepted in 2012-04-03,  发布年份 2012

【 摘 要 】

Background

In France, the rapid scale-up of buprenorphine, an opioid maintenance treatment (OMT), in primary care for drug users has led to an impressive reduction in HIV prevalence among injecting drug users (IDU) but has had no major effect on Hepatitis C incidence. To date, patients willing to start methadone can only do so in a methadone clinic (a medical centre for drug and alcohol dependence (CSAPA) or a hospital setting) and are referred to primary care physicians after dose stabilization. This study aims to assess the effectiveness of methadone in patients who initiated treatment in primary care compared with those who initiated it in a CSAPA, by measuring abstinence from street opioid use after one year of treatment.

Methods/Design

The ANRS-Methaville study is a randomized multicenter non-inferiority control trial comparing methadone induction (lasting approximately 2 weeks) in primary care and in CSAPA. The model of care chosen for methadone induction in primary care was based on study-specific pre-training of all physicians, exclusion criteria and daily supervision of methadone during the initiation phase. Between January 2009 and January 2011, 10 sites each having one CSAPA and several primary care physicians, were identified to recruit patients to be randomized into two groups, one starting methadone in primary care (n = 147), the other in CSAPA (n = 48). The primary outcome of the study is the proportion of participants abstinent from street opioids after 1 year of treatment i.e. non-inferiority of primary care model in terms of the proportion of patients not using street opioids compared with the proportion observed in those starting methadone in a CSAPA.

Discussion

The ANRS-Methaville study is the first in France to use an interventional trial to improve access to OMT for drug users. Once the non-inferiority results become available, the Ministry of Health and agency for the safety of health products may change the the New Drug Application (NDA) of methadone and make methadone induction by trained primary care physicians possible.

The trial is registered with the French Agency of Pharmaceutical Products (AFSSAPS) under the number 2008-A0277-48, the European Union Drug Regulating Authorities Clinical Trials.

Number Eudract 2008-001338-28, the ClinicalTrials.gov Identifier: NCT00657397 and the International Standard Randomised Controlled Trial Number Register ISRCTN31125511.

【 授权许可】

   
2012 Roux et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, (2):CD002207.
• [2]Michel L, Roux P, Cohen J, Carrieri MP: A French prospective observational study of the treatment of chronic hepatitis C in drug abusers: a commentary. Gastroenterol Clin Biol 2009, 33(1 Pt 1):15-16. author reply 16–17.
• [3]Carrieri MP, Amass L, Lucas GM, Vlahov D, Wodak A, Woody GE: Buprenorphine use: the international experience. Clin Infect Dis 2006, 43(Suppl 4):S197-S215.
• [4]Emmanuelli J, Desenclos JC: Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 2005, 100(11):1690-1700.
• [5]Roux P, Villes V, Bry D, Spire B, Feroni I, Marcellin F, Carrieri MP: Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict Behav 2008, 33(12):1625-1629.
• [6]Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A: Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003, 69(2):175-181.
• [7]Gossop M, Marsden J, Stewart D, Kidd T: The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction 2003, 98(3):291-303.
• [8]Hubbard RL, Craddock SG, Anderson J: Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003, 25(3):125-134.
• [9]Gossop M, Marsden J, Stewart D, Lehmann P, Strang J: Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study. Br J Gen Pract 1999, 49(438):31-34.
• [10]Weinrich M, Stuart M: Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy. JAMA 2000, 283(10):1343-1348.
• [11]Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS: Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001, 286(14):1724-1731.
• [12]Strain EC, Bigelow GE, Liebson IA, Stitzer ML: Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999, 281(11):1000-1005.
• [13]Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, Wood E: Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend 2007, 87(1):39-45.
• [14]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33. quiz 34–57.
• [15]Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S: The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis 2008, 27(3):37-48.
• [16]Leavitt SB: Methadone-Drug Interactions. Forum: In Addiction Treatment; 2005.
• [17]Trafton JA, Ramani A: Methadone: a new old drug with promises and pitfalls. Curr Pain Headache Rep 2009, 13(1):24-30.
• [18]Groves RM, Mathiowetz NA: Chapter V. A comparison of CATI and non-CATI questionnaires. Vital and health statistics 1987, (106):33-39.
• [19]Darke S, Hall W, Wodak A, Heather N, Ward J: Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992, 87(5):733-742.
• [20]Fry CL, Lintzeris N: Psychometric properties of the Blood-borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ). Addiction 2003, 98(2):171-178.
• [21]Stoove MA, Fry CL, Lintzeris N: Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention. Harm Reduct J 2008, 5:12. BioMed Central Full Text
• [22]Lucidarme D, Foutrein P, Creusy C, Forzy G, Foutrein-Comes MC, Muyssen A, Bailly D, Parquet PJ, Filoche B: Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts. Gastroenterol Clin Biol 1994, 18(11):964-968.
• [23]Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, Delamare C, Cyran C, Van Hoenacker AF, Fremaux D, et al.: Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 2004, 132(4):699-708.
• [24]Fuhrer R, Rouillon F: La version française de l’échelle CES-D. Description and translation of the autoevaluation scale (in French). Psychiatrie et Psychobiologie 1989, 4:163-166.
• [25]Beck AT, Steer RA, Kovacs M, Garrison B: Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry 1985, 142(5):559-563.
• [26]Roberti JW, Storch EA, Bravata E: Further psychometric support for the Sensation Seeking Scale–Form V. J Pers Assess 2003, 81(3):291-292.
• [27]Etter JF, Duc TV, Perneger TV: Validity of the Fagerstrom test for nicotine dependence and of the Heaviness of Smoking Index among relatively light smokers. Addiction 1999, 94(2):269-281.
• [28]Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M: Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption–II. Addiction 1993, 88(6):791-804.
• [29]Poundja J, Fikretoglu D, Guay S, Brunet A: Validation of the French version of the brief pain inventory in Canadian veterans suffering from traumatic stress. J Pain Symptom Manage 2007, 33(6):720-726.
• [30]Smith MY, Winkel G, Egert J, Diaz-Wionczek M, DuHamel KN: Patient-physician communication in the context of persistent pain: validation of a modified version of the patients’ Perceived Involvement in Care Scale. J Pain Symptom Manage 2006, 32(1):71-81.
• [31]Gossop M: The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav 1990, 15(5):487-490.
• [32]Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220-233.
• [33]Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, et al.: The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005, 35(2):245-256.
• [34]Smyth BP, Barry J, Lane A, Cotter M, O’Neill M, Quinn C, Keenan E: In-patient treatment of opiate dependence: medium-term follow-up outcomes. Br J Psychiatry 2005, 187:360-365.
• [35]Maremmani I, Pani PP, Pacini M, Perugi G: Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat 2007, 33(1):91-98.
• [36]Wittchen HU, Apelt SM, Soyka M, Gastpar M, Backmund M, Golz J, Kraus MR, Tretter F, Schafer M, Siegert J, et al.: Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 2008, 95(3):245-257.
• [37]Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chene G, Spire B: Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006, 41(4):477-485.
• [38]Protopopescu C, Marcellin F, Spire B, Preau M, Verdon R, Peyramond D, Raffi F, Chene G, Leport C, Carrieri MP: Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res 2007, 16(4):577-591.
• [39]Caplehorn JR, Drummer OH: Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999, 170(3):104-109.
• [40]Cornish R, Macleod J, Strang J, Vickerman P, Hickman M: Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010, 341:c5475.
• [41]Morgan OW, Johnson H, Rooney C, Seagroatt V, Griffiths C: Changes to the daily pattern of methadone-related deaths in England and Wales, 1993–2003. J Public Health (Oxf) 2006, 28(4):318-323.
• [42]Greenwood J: Creating a new drug service in Edinburgh. BMJ 1990, 300(6724):587-589.
• [43]Lawrinson P, Roche A, Terao H, Le PP: Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Drug Alcohol Rev 2008, 27(1):47-53.
• [44]Sheridan J, Manning V, Ridge G, Mayet S, Strang J: Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995–2005. Addiction 2007, 102(11):1824-1830.
• [45]Bonnet N: Pharmacy syringe exchange program for injection drug users. Presse Med 2006, 35(12 Pt 1):1811-1818.